Neena M. Patil Sells 5,000 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $110.70 on Thursday. The company has a market capitalization of $6.98 billion, a P/E ratio of 22.82, a price-to-earnings-growth ratio of 1.53 and a beta of 0.63. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The firm has a 50 day moving average of $115.18 and a 200 day moving average of $120.55. Jazz Pharmaceuticals plc has a twelve month low of $103.01 and a twelve month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. As a group, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in JAZZ. SG Americas Securities LLC bought a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $611,000. Commonwealth Equity Services LLC boosted its holdings in Jazz Pharmaceuticals by 10.6% in the third quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company’s stock worth $1,304,000 after purchasing an additional 962 shares during the last quarter. Forsta AP Fonden boosted its holdings in Jazz Pharmaceuticals by 15.2% in the third quarter. Forsta AP Fonden now owns 22,000 shares of the specialty pharmaceutical company’s stock worth $2,848,000 after purchasing an additional 2,900 shares during the last quarter. Strs Ohio boosted its holdings in Jazz Pharmaceuticals by 4.4% in the third quarter. Strs Ohio now owns 14,119 shares of the specialty pharmaceutical company’s stock worth $1,827,000 after purchasing an additional 593 shares during the last quarter. Finally, Advisor Partners II LLC purchased a new stake in Jazz Pharmaceuticals in the third quarter worth approximately $231,000. Institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on JAZZ shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Truist Financial reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. UBS Group decreased their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research note on Friday, March 1st. Finally, Barclays decreased their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.75.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.